Alzheimer’s Association Funding Program for Global Real-World Data Platforms (ALZ-RWD)

Contents

1. Program Objective
2. Program Overview
3. Funding and Award Period
4. Eligibility
5. Submission and Review Process
6. Ethical and Regulatory Approvals and Reporting Requirements
7. Additional Information

1. Program Objective

The collection of Real-World Data (RWD) is integral to the discovery, evaluation and evolution of novel avenues for the diagnosis, prevention, treatment and care of Alzheimer’s and other dementia. This includes understanding the long-term effects of any new treatment approach. Furthermore, RWD can play a key role in the identification and understanding of health disparities, and the subsequent development and implementation of initiatives to advance health equity.

Real world data (RWD) platforms house data on patient health status and health care collected within real-world settings. To support the advancement of and opportunities for RWD platforms, the Alzheimer’s Association is launching a peer-reviewed funding program to augment and accelerate global initiatives aimed at developing, expanding and aligning RWD platforms’ infrastructure, data and impact.

2. Program Overview

In late 2021, the Alzheimer’s Association launched the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) to connect clinical data from Alzheimer’s patients to a network of medical professionals and researchers to encourage robust information sharing and education, and to drive innovation in the ways we care for and treat Alzheimer’s disease and other dementia. To build on the global momentum in this field, the ALZ-RWD funding program aims to advance RWD by providing funds to develop, expand, and align RWD platforms’ infrastructure, data and impact globally.

Potential projects will differ depending upon the specific aims and stage of development of the individual RWD platform. Eligible projects should relate to the following areas of focus, but other projects will be considered:

- Platform development (e.g., feasibility studies)
- Platform expansion (e.g., the addition of modules to existing platforms in order to collect RWD on newly-approved treatments)
- Platform utilization (e.g., site start-up payments to incentivize platform utilization, or the production of educational materials)
- Data collection (e.g., the addition of remote data collection or biomarker assessments, salaries for technical staff)
- Data integration and linking (e.g., with electronic health records)
Data analysis and publication (e.g., research studies)

For all applications, priority will be given to proposals that enhance harmonization and collaboration across global platforms and have the potential to advance health equity (e.g., support ensures that a platform’s population is representative of a defined community).

3. Funding and Award Period

The Alzheimer’s Association has allocated up to USD $5,000,000 to fund the ALZ-RWD Program over the next three years, and will accept submissions on a rolling basis.

As the scope and duration of funding will differ with each individual application, it is anticipated that funding will range from USD$100,000 up to a maximum grant amount of USD$1,000,000. Project duration is 12-24 months. Each RWD platform is limited to one unique award through this program’s first iteration; with potential for follow-on funding.

Awarded projects will be evaluated on progress toward specific milestones; continued disbursement of funds is dependent on demonstrated progress toward key milestones.

Allowable costs under this award include:

- IT and related costs for platform establishment or expansion, including data access related fees
- Computer software if used strictly for data collection and/or analysis.
- Salary for the principal investigator, scientific (including postdoctoral fellows) and technical staff (including modest administrative support).
- Research supplies needed for the proposed studies.
- Support for travel to scientific and professional meetings, not to exceed $5,000 over a two-year period.
- Open access publications fees.

Not allowable as direct costs under this award include:

- Computer hardware or standard software (e.g. Microsoft Office, mouse monitor, computer parts)
- Laboratory equipment such as freezers, ultracentrifuges, RT-PCR, Microscopy/imaging equipment
- Service contract fees of equipment
- Construction or renovation costs
- Tuition
- Rent for laboratory/office space
- Expenses such as Data Network Recharges and Computing and communication device support services
- General liability insurances, such as GAEL
- Wire and currency exchange fees
- Salary and/or compensation for Alzheimer’s Association Staff or current members of the Alzheimer’s Association Medical and Scientific Advisory Group (MSAG) and the International Research Grant Program (IRGP) Council. A complete list of MSAG and IRGP Council members can be found on our website alz.org/grants.

No indirect costs are allowed.
4. Eligibility

In order to be eligible for ALZ-RWD funding, proposals must

- Support the infrastructure, data and / or impact of a RWD platform that
  - Has, or plans to have, international, national or significant regional reach
  - Houses, or aims to house, data collected in real-world settings on patient health status and healthcare; including, for example, data from patient surveys, electronic health records (EHRs), administrative claims, digital health technologies and / or other sources
  - Comprises a physician or patient registry, or a cohort study; clinical trial databases are not eligible for this funding program
- Enhance alignment and collaboration between global platforms, including with ALZ-NET
  - Please note, the Association requires data sharing / connection (in line with international sharing laws) through GAAIN (gaain.org)
  - The ALZ-RWD funding program aims to complement Alzheimer’s Association initiatives to convene global RWD platforms. Interested applicants are encouraged to email Claire Sexton (csexton@alz.org) for the latest information on activities and opportunities prior to any application
- Have the potential to advance health equity
  - For example, by ensuring that the platform’s population is representative of a defined community
- Include a Principal Investigator who is a full-time faculty member or full-time paid employee of the organization submitting the proposal.

Note: Investigators that have received Alzheimer’s Association funding for a related or other study and are currently delinquent in submitting required reports or have awards closed as “Incomplete” are not eligible to apply. For questions about eligibility, please contact the Alzheimer’s Association at grantsapp@alz.org and note that you are seeking clarification regarding the ALZ-RWD program eligibility.

5. Submission and Review Process

5.1. Summary

Pre-submission inquiries are welcome at any time and will be reviewed by the Alzheimer’s Association with appropriate experts to evaluate the eligibility, feasibility, and potential impact of a proposal. Successful pre-submission inquiries will be invited to submit a full application, with deadlines discussed with application PI. Full applications will be reviewed by an expert group and panel for consideration to make recommendations to the Alzheimer’s Association

If a submission is not accepted, the application is allowed up to two resubmissions.
5.2. Pre-Submission Inquiries

Pre-submission inquiries are welcome at any time via the Pre-Submission Inquiry Survey, which collects information on
- The applicant team (PI, team, expertise)
- The RWD platform (name; country; status; brief descriptions of the platform, population and data sources; goals; team)
- The funding request (overview; brief descriptions of how support will have the potential to advance health equity and enhance alignment and collaboration between global platforms; current and potential sources of funding)
- Other relevant information.

5.3. Full Applications

For those invited to submit a full application, additional materials will be required. Templates, instructions and application deadlines will be provided after approval of the pre-submission inquiry.

5.4. Appeals of Scientific Peer Review

To maintain a fair and rigorous review system, the Alzheimer’s Association has a process for appeal of funding decisions. Appeals will not be considered for the pre-submission inquiries stage. Regarding full applications, an appeal is intended to address extraordinary circumstances. Appropriate reasons for initiating an appeal might include:
- Evidence that a reviewer has an undeclared conflict of interest.
- An egregious error or misunderstanding in the review process.
- Active malfeasance or demonstrable lack of due diligence.

The appeal process is not intended to provide a mechanism for routine protest of failure to receive a grant.

If an applicant believes an extraordinary circumstance has contributed to failure to receive funding, the principal investigator may send a two-page, double-spaced formal letter of appeal (Word document) to grantsappeals@alz.org. Any supporting documents included must be submitted as a PDF. **Appeals must be submitted within 2 weeks from the date your application outcome notification is sent.** Notification of action on the appeal will be made via email, usually within 90 days of the appeal deadline.

6. Ethical and Regulatory Approvals and Reporting Requirements

If awarded for funding, the Alzheimer’s Association requires that any necessary ethical and/or regulatory approvals are kept current, and may require specific reporting throughout the lifetime of the award. This includes, but is not limited to, the following:

6.1. Human Participants / Volunteers Ethical Assurances

Human participants / volunteers ethical assurances are not required at the time of application. Investigators have up to 90 days after receipt of their award notification to submit these documents.
However, the Alzheimer’s Association encourages investigators to initiate their certification applications on a schedule that recognizes that approvals at many institutions can take more than 90 days. We will accept only certifications that apply specifically to the funded project and must include the name of the awardee. An award letter will not be issued unless the appropriate certifications are in place and include the name of the awardee within the 90 days from award notification.

### 7.3 Diversity and Representation

Diversity and representation will be tracked throughout the duration of the grant and continued funding is contingent on progress towards advancing health equity. RWD platform populations should aim to be representative of a defined community – and consider diversity as appropriate, for example with regard to sex, gender identity, sexual orientation, socioeconomic status, race, and / or ethnicity. In addition, research studies utilizing the RWD platform must include appropriate inclusion or exclusion criteria.

### 6.2. Financial Responsibility

Funding is awarded to the institution and/or organization, not to the individual principal investigator. The principal investigator or a first-degree relative cannot be listed as the signing official or financial officer, or have checks sent to their attention if awarded.

### 6.3. Annual Scientific and Financial Reports

Interim Scientific and Financial Reports must be submitted at the end of each reporting period as long as the grant remains active. Final Scientific and Financial Reports must be filed within 90 days of the grant’s end date. All reports must be submitted electronically via proposalcentral.com. The Financial Report must be approved and signed by someone with financial authority in the Office of Research and Sponsored Programs at the recipient’s institution.

It is expected that award recipients will participate in Alzheimer’s Association meetings and conferences, including the Alzheimer’s Association International Conference (AAIC).

### 7. Additional Information

#### 7.1. Nondiscrimination and Harassment Statement

The Alzheimer’s Association is committed to providing an environment free from harassment and discrimination. Alzheimer’s Association strictly prohibits harassment and discrimination based on race; creed; color; religion; sex; sexual orientation; national origin; ancestry; age; Veteran status; citizenship status; marital status; physical or mental disabilities; pregnancy, gender identity or expression (including transgender status); genetic information; and any other characteristic protected by federal, state or local law.

#### 7.2. Further information

Please contact the Alzheimer’s Association at [grantsapp@alz.org](mailto:grantsapp@alz.org) with any questions.